Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
158.00
-10.00 (-5.95%)
Mar 4, 2026, 1:30 PM CST
-30.09%
Market Cap 28.30B
Revenue (ttm) 35.83M
Net Income (ttm) -340.54M
Shares Out 168.46M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 316,002
Average Volume 283,179
Open 164.00
Previous Close 168.00
Day's Range 158.00 - 164.00
52-Week Range 122.00 - 329.50
Beta 0.04
RSI 32.83
Earnings Date Mar 11, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that is in Phase Ib/II clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and CS028, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements

News

There is no news available yet.